ORBAX® ORAL SUSPENSION

(orbifloxacin)

Once-a-day oral suspension for cats and small dogs containing orbifloxacin, a synthetic broad-spectrum antibacterial agent.

Orbax Oral Suspension Bottle & Syringe

Overview

Pharmaceutical Name

Orbifloxacin

ORBAX Oral Suspension. Once-a-day, broad spectrum antibiotic therapy ideal for cats and small dogs.

Indications

  • Skin infections (wounds and abscesses) in cats.*2
  • Skin and soft tissue infections (wounds and abscesses) and urinary tract infections (cystitis) in dogs.*3

*Caused by susceptible strains of bacteria as listed in approved indications. Please see the Package Insert for full prescribing information.

Features and Benefits

  • No refrigeration, no need to reconstitute.
  • Tasty malt-flavored antibiotic for easy administration.1
  • Patented Ion Exchange taste-masking technology – Orbifloxacin is bound to a taste-masking agent so it passes taste buds undetected, then is released in the low pH environment of the stomach.
  • Convenient once-daily dosing:
    • Cat: 3.4 mg/lb (7.5 mg/kg) per day.2
    • Dog: 1.1-3.4 mg/lb (2.5-7.5 mg/kg) per day.3
  • Rapid broad-spectrum bactericidal activity.2,3

Species: Canine, Feline

IMPORTANT SAFETY INFORMATION:

Quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. Orbifloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation, which may lead to convulsive seizures. The use of fluoroquinolones in cats has been reported to adversely affect the retina and should be used with caution in cats. Blindness has also been reported post-approval in cats. In some cases, blindness has been temporary. See Package Insert for full information including side effects, precautions, warnings, and contraindications.

References:

  1. Data on file. Multi-clinic, randomized, controlled field trail evaluating the use of ORBAX® (orbifloxacin) Oral Suspension and Synulox® (amoxicillin/clavulanate) in the treatment of cats with skin and soft tissue infections (primarily post-traumatic wounds and absesses) in France, Belgium, and Germany in 2001. Madison, NJ: Intervet Inc.
  2. Prescribing information for ORBAX® Oral Suspension for Oral Use in Cats. Madison, NJ: Intervet Inc. 2011.
  3. Prescribing information for ORBAX® Oral Suspension for Oral Use in Dogs. Madison, NJ: Intervet Inc. 2011.